Wordt geladen...
Efficacy of eplerenone in the management of mineralocorticoid excess in men with metastatic castration resistant prostate cancer treated with abiraterone without prednisone
Prednisone is typically co-administered with abiraterone in treatment of castrate resistant prostate cancer to prevent toxicities of secondary mineralocorticoid excess. However, many patients do not desire or cannot tolerate chronic glucocorticoid therapy. In this retrospective study, we report that...
Bewaard in:
| Gepubliceerd in: | Clin Genitourin Cancer |
|---|---|
| Hoofdauteurs: | , , , , , , , , , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
2017
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5501307/ https://ncbi.nlm.nih.gov/pubmed/28131750 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.clgc.2016.12.008 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|